Suven Life Sciences Ltd

- There is no mention of any current or planned fundraising through debt or equity in the provided transcript. - The management did not discuss raising capital via debt or equity during the call. - They highlighted ongoing investments in CAPEX (~Rs. 100 crore for FY18 and similar for FY19) funded through operational means. - The focus remains on progressing clinical trials and business growth without reference to external fundraising. - Any future financing needs were not addressed or indicated in this transcript.

- Suven Life Sciences is constructing an additional block to accommodate new requirements for high potency compounds. - The planned capital expenditure (CAPEX) for this expansion is approximately Rs. 120 crore. - As of the date of the call, around Rs. 25-30 crore has already been spent with orders placed and equipment arriving. - The bulk of this CAPEX will be incurred over the next two quarters, with some spillover into the next financial year. - Total CAPEX for FY18 is expected to be around Rs. 90-100 crore. - For FY19, a similar range of CAPEX is anticipated, including maintenance and spillover costs of Rs. 20-30 crore. - No other specific strategic investments were mentioned in this transcript.

- Suven Life Sciences expects overall topline growth of 5% to 10% for the next 6 months and potentially beyond. - CRAMS (Contract Research and Manufacturing Services) business is expected to grow by around 10%, compensating for the decline in Specialty Chemicals. - Specialty Chemicals segment is anticipated to see a 20%-25% de-growth for FY18 due to generic competition, stabilizing post this decline. - Repeat business (commercial launches) guidance is around Rs. 70 crore for FY18, with a possibility of increase by Rs. 10-15 crore. - Patient enrollment for Phase-2 clinical trials is progressing, with completion expected by late 2018 and data results by mid-2019, which may impact future growth. - Incremental growth also anticipated from preclinical compounds moving to Phase-1 clinical trials and planned Phase-2 trials for new molecules starting next year.

- Suven Life Sciences expects overall topline growth of 5% to 10% in the next 6 months. - Bottom-line (profit) growth is guided at up to 20% over the same period. - EBITDA margins are expected around 35% for FY18. - Core CRAMS segment EBITDA margins projected above 30%, potentially around 39% for the half year. - Specialty Chemicals segment is expected to decline by 20-25% in FY18 due to generic competition but will stabilize thereafter. - Repeat orders (commercial launches) are projected around Rs. 70 crore for FY18, with potential to increase slightly. - The company anticipates improved product mix and increased repeat orders to drive margins and profitability. - R&D spend expected to remain steady around Rs. 60 crore annually. - CAPEX guidance is approximately Rs. 90-100 crore for FY18, with similar levels expected next year.

- Current orderbook details are not explicitly specified in the transcript. - Pending orders: Mentioned a pending order of about Rs. 30 crore related to commercial launches (Page 8). - Repeat orders for FY18 expected around Rs. 70 crore, with a possibility to increase by Rs. 10-15 crore (Page 5). - CRAMS revenue for the quarter is Rs. 91.7 crore, including Rs. 16 crore from repeat orders (Page 10, 7). - Specialty Chemicals de-growth expected at 20-25% for the full year, leading to lower orders in this segment (Page 2, 7). - The company anticipates 5%-10% topline growth overall in FY18, indicating some new orders or ramp-ups compensating for declines (Page 11).